GABAB receptors are up-regulated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders?
References (27)
- et al.
Brain GABAergic and dopaminergic systems following lithium treatment and withdrawal
Prog. Neuro-Psychopharmacol.
(1981) - et al.
[3H](−)-Baclofen: An improved ligand for GABA sites
Neuropharmacology
(1985) - et al.
Evidence for two types of binding of 3H-GABA and 3H-muscimol in rat cerebral cortex and cerebellum
Life Sci.
(1979) - et al.
Effects of carbamazepine and valproic acid on brain immunoreactive somatostatin and γ-aminobutyric acid in amygdala-kindled rats
European J. Pharmacol.
(1986) - et al.
Phaclofen: a peripheral and central baclofen antagonist
Brain Res.
(1987) - et al.
Protein measurement with the Folin phenol reagent
J. Biol. Chem.
(1951) - et al.
Acute and short-term effects of lithium on glutamate metabolism in rat brain
Biochem. Pharmacol.
(1986) - et al.
Plasma GABA: A possible indicator of altered GABA function in psychiatric illness
Neuropharmacology
(1984) Lithium in psychiatric therapy and prophylaxis
J. Psychiat. Res.
(1968)- et al.
Chronic administration of the GABA-transaminase inhibitor ethanolamine O-sulphate leads to up-regulation of GABA binding sites
Biochem. Pharmacol.
(1984)
The GABA hypothesis of affective illness: influence of clinically effective antimanic drugs on GABA turnover
Reduced plasma and CSF γ-aminobutyric acid in affective illness: Effect of lithium carbonate
Biol. Psychiat.
Characteristics of GABAB receptor binding sites on rat whole brain synaptic membranes
Br. J. Pharmacol.
Cited by (84)
Impacts of climate change-abiotic factors on the effects caused by pharmaceutical residues to marine organisms
2021, Pharmaceuticals in Marine and Coastal Environments: Occurrence, Effects, and Challenges in a Changing WorldYoga: Balancing the excitation-inhibition equilibrium in psychiatric disorders
2019, Progress in Brain ResearchEffects of carbamazepine and cetirizine under an ocean acidification scenario on the biochemical and transcriptome responses of the clam Ruditapes philippinarum
2018, Environmental PollutionCitation Excerpt :The toxicity of drug exposure (CBZ and CTZ) and OA, under actual and predicted OA conditions, based on their MoA was evaluated through changes in the mRNA levels, which showed to be affected by pH and both drugs. Despite that the main target of CBZ are the voltage-dependent Na+ channels, this drug has also been referred to interact with Ca+ and K+ channels (Beutler et al., 2005); to modulate release, uptake and receptor binding of neurotransmitters as GABA (γ-aminobutyric acid) (Ambrósio et al., 2002; Motohashi et al., 1989); to inhibit adenylate cyclase activity (Palmer, 1979); to decrease arachidonic acid turnover (Bazinet et al., 2006) and to inhibit the histone deacetylases (Beutler et al., 2005). Previous studies found that CTZ inhibits the H1-receptor-mediated nuclear factor-kappa b (NF-kB); reduces allergen-induced eosinophil (inflammatory cells) accumulation (through down-regulation of NF-kB) and inhibits the generation of cytokines as TNF- α (tumor necrosis factor) (Leurs et al., 2002).
The potential efficacy of GABA<inf>B</inf> antagonists in depression
2017, Current Opinion in PharmacologyBrain anticonvulsant protection of mice given chronic carbamazepine under various fatty acid and magnesium diet conditions
2012, Prostaglandins Leukotrienes and Essential Fatty AcidsCitation Excerpt :An ESM-like profile was previously observed for n-3 PUFA diet and was suggested to result from known inhibitory effects of ALA and EPA on t-type Ca++ channels [13]. Though CBZ does not directly act on the t-type Ca++ channel, this drug, like lithium, up-regulates metabotropic GABAB receptors [38]. These receptors are well known to inhibit voltage-dependent calcium channels [39] including the T-type Ca++ channel, a major pharmacological target of ESM [40–42], providing a coherent explanation for the ESM-like profile exhibited by CBZ under MUFA and n-3 PUFA diets as indicated in the panel A of Fig. 3.
The NMDA receptor/nitric oxide pathway: A target for the therapeutic and toxic effects of lithium
2011, Trends in Pharmacological Sciences